| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.056 | 0.8 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |